Home > Case Content

Research Results and Publications

Applications from National Biobank Consortium of Taiwan

Application No. (NBCT No.)	Principal Investigator	Affiliation & Department	Title of the Project
NB2020001 (NBCT No.200016)	Gigin Lin	Radiology, Chang Gung Medical Foundation	Precision medicine for human gastric and colon cancers: Integrated metabolomics and morphomics imaging analysis
NB2022001 (NBCT No.220079)	Huang, Yen Chun	Operation management, Marker Exploration Corp.	Clinical Utility of Plasma Cancer Proteomic Profile for Early Detecting Multiple Primary Cancer
NB2022002 (NBCT No.220080)	Chi-Cheng Huang	Comprehensive Breast Health Center, Taipei Veterans General Hospital	New drug development guided from biomedical big data
NB2022003 (NBCT No.220095)	Wayne Hsieh	Medical Solution Cluster, Roche Product Ltd.	Research and application of oncology clinico-genomic big database
NB2022004 (NBCT No.220089)	Yi-Hsin Yang	National Institute of Cancer Research, National Health Research Institutes	Data governance for cancer-specific data in National Biobank Consortium in Taiwan
NB2022005 (NBCT No.220098)	Tian-Lu Cheng	Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University	Precising the pro-antibody engineering by computer simulation, X-ray crystallography and cryogenic electron microscopy to comprehensively improve the disease selectivity and reduce the side effects of antibody drugs
NB2023001 (NBCT No. 230110)	Ren-Hua Chung	Institute of Population Health Sciences, National Health Research Institutes	Multi-omics analysis to identify novel immune genes for triple-negative breast cancer and functionally validating their roles in cancer subtyping, tumorigenesis and immune microenvironment
NB2023002 (NBCT No. 230113)	Shiu-Wen Huang	Department of Research and development, Taipei Medical University Hospital	Application of novel natural naphthoquinone-based derivatives as anti-angiogenic, anti-lymphogenic and anti-tumor agents and its underlying mechanisms
NB2023003 (NBCT No. 230115)	Tang-Yuan Chu	Department of Obstetric & Gynecology, Tzu Chi Hospital, Hualien	FE25 cell transformation as a serum bioassay to detect cancers and estimate tumor load: a validation study and characterization of the transformation activity
NB2023004 (NBCT No.230126)	Kun-Yu Lai	Department of Optics and Photonics, National Central University	High throughput Raman spectroscopy: A new DNA testing for cancers and cord blood
NB2024001 (NBCT No.230125)	Huamei Chang	Research & Development, SP BioMED Co. Ltd.	Polygenic risk score for early onset breast cancer of Taiwan
NB2024002 (NBCT No.240140)	Yu-Shan Wang	General Manager Office, UniPharma Co. Ltd.	Analysis of the differential expression of the DR-70 tumor marker in various cancer patients compared to a healthy population, utilizing serum samples from the National Biobank Consortium of Taiwan
NB2024003 (NBCT No.240136)	Ming-Fang Wu	Department of Internal Medicine, Chung Shan Medical University Hospital	Using comprehensive cancer genetic testing and national biobank consortium of Taiwan database information to explore the genetic variation expression, clinical manifestations and treatment results of Taiwan's six advanced cancer patients

Publications

1. Su SC, Lin CW, Liu YF, Fan WL, Chen MK, Yu CP, Yang WE, Su CW, Chuang CY, Li WH, Chung WH, and Yang SF. Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities. Theranostics 2017; 7(5):1088-99.

2. Chang PY, Chen CC, Chang YS, Tsai WS, You JF, Lin GP, Chen TW, Chen JS*, Chan EC*. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. Oncotarget. 2016 Mar 1;7(9):10663-75.

3. Chang PY, Chen JS, Chang NC, Chang SC, Wang MC, Tsai SH, Wen YH, Tsai WS, Chan EC*, Lu JJ*. NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencing. Oncotarget. 2016 Jun 21;7(25):37566-37580.

4. Wu-Chou YH, Lu YC, Chen KP, Chang HF, Lin YT, Lo LJ. Association Studies Between Regulatory Regions of IRF6/TP63 Genes and Nonsyndromic Oral Clefts. Cleft Palate Craniofac J. 2019 Jul;56(6):778-785. Epub 2018 Nov 12.

5. Wei KC, Chen CY, Feng LY, Huang WT, Chen CH, Hsu PW, Wang K, Hood LE, Chen LY. The rs16906252: C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort. PLoS One. 2017 Jun 2;12(6):e0178842. eCollection 2017.

6. Yu MC, Lee CW, Lin CH, Wu CH, Lee YS, Tsai CL, Tsai CN. Differential hypermethylation of the VTRNA2-1 promoter in hepatocellular carcinoma as a prognostic factor: Tumor marker prognostic study. Int J Surg. 2020 Jul; 79:282-289. Epub 2020 May 14.

7. Fan WL, Yang LY, Hsieh JC, Lin TC, Lu MJ, Liao CT*. Prognostic Genetic Biomarkers Based on Oncogenic Signaling Pathways for Outcome Prediction in Patients with Oral Cavity Squamous Cell Carcinoma. Cancers (Basel). 2021 May 30;13(11):2709.

8. Wu MJ, Chen CJ, Lin TY, Liu YY, Tseng LL, Cheng ML, Chuu CP, Tsai HK, Kuo WL, Kung HJ, Wang WC. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer. Theranostics. 2021 Jun 26;11(16):7779-7796. eCollection 2021.

9. Liao CT, Yang LY, Lee LY, Lin CY, Wang HM, Ng SH, Yen TC, Fan WL*, Hsieh JC*. Whole-exome sequencing identifies biosignatures that predict adverse survival outcomes in surgically treated patients with oral cavity squamous cell carcinoma. Oral Oncol. 2021 Nov;122:105547. Epub 2021 Oct 23.

(update: 11/25/2024)